^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GD2-CART

i
Other names: GD2-CART, GD2 CAR T, GD2CART
Associations
Trials
Company:
Stanford University
Drug class:
GD2-targeted CAR-T immunotherapy
Associations
Trials
9ms
Rejuvenated iPSC-derived GD2-directed CART cells harbor robust cytotoxicity against small cell lung cancer. (PubMed, Cancer Res Commun)
Dual blockade of TIGIT and programmed death-1 (PD-1) increased the cytotoxicity of GD2-CARTs to some extent, suggesting that low TIGIT and PD-1 expression of GD2-CARrejTs is a major factor required for robust cytotoxicity against SCLC. Not only for robust cytotoxicity but also for availability as "off-the-shelf" T cell therapy, iPSC-derived GD2-CARrejTs are a promising novel treatment for SCLC.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-1 expression • TIGIT expression
|
GD2-CART
11ms
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. (PubMed, Cancer Cell)
Longitudinal analysis of post-treatment samples identified increased CXCR3 classical monocytes in all groups as CAR-T numbers waned. Together, our data uncover mediators of CAR-T biology and correlates of expansion that could be utilized to advance immunotherapies for solid tumor patients.
Journal • CAR T-Cell Therapy
|
CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
GD2-CART
over1year
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing. (PubMed, Mol Cancer)
Our work provides a novel platform to perform guided CAR insertion into primary human T-cells using nanoplasmid DNA and holds the potential to increase access to CAR-T cell therapies.
Journal • CAR T-Cell Therapy
|
GD2-CART
over1year
Immune determinants of CAR-T expansion in solid tumor patients receiving GD2 CAR-T cell therapy (AACR 2023)
CXCR3 has been extensively studied on T cells, but its function on myeloid populations is yet to be fully explored. These results are the first to demonstrate that the peripheral immune environment prior to CAR-T administration may effectively predict and modulate CAR-T expansion in patients.
Clinical • CAR T-Cell Therapy • IO biomarker
|
CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
CXCR3 overexpression
|
GD2-CART
over1year
Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients (AACR 2023)
H3K27M-mutated DIPG/DMG patients demonstrate continued clinical response with serial ICV GD2 CAR-T infusions, with heterogeneity in the durability of response across patients. In-depth correlative analyses profile distinct immune populations and demonstrate population shifts depending on route of administration and over the course of treatment. Key findings from these data will allow for iterative improvement in CAR-T therapies for H3K27M+ DIPG/DMG patients, providing hope to shift the paradigm of this fatal disease.
Clinical • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL2 (Chemokine (C-C motif) ligand 2)
|
GD2-CART